You are here: Industry Insights > COVID-19

News List

Florida Blue Providing $50 Million in Health Care Cost Relief to Commercial Fully Insured Customers prnewswire
June 11, 2020
Florida Blue, the state's leading health insurer, announced additional actions being taken in response to the COVID-19 pandemic.
NHS waiting lists could hit 10m by year end pharmatimes
June 11, 2020
NHS waiting lists could swell to 10 million by the end of the year, and possibly higher if there is a second wave of COVID-19 and a lack of treatment or a vaccine, the NHS Confederation warns.
MMS to support IGY Life Sciences in advancing Covid-19 antibody candidate pharmaceutical-business-review
June 11, 2020
IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.
COVID-19 mouse model will speed search for drugs, vaccines worldpharmanews
June 11, 2020
The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19.
TRICCAR Releases Results Of Study Of AVL? Anti-Viral Supplement prnewswire
June 11, 2020
As the United States and world continue to struggle with the ongoing effects of the COVID-19 pandemic, TRICCAR, Inc. (OTC: FOSI), announces the results of a double-blind placebo-controlled study of AVL?.
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients americanpharmaceuticalreview
June 11, 2020
Agenus announced the U.S. Food and Drug Administration’s (FDA) clearance of AgenTus' IND application for an allogeneic iNKT therapy.
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials europeanpharmaceuticalreview
June 11, 2020
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
Daewoong finds niclosamide effective against Covid-19 in animal tests pharmaceutical-technology
June 11, 2020
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
Catalent Enters COVID-19 Vax Pact with Spicona contractpharma
June 11, 2020
Will leverage GPEx cell line development platform to develop COVID-19 vaccine.
Why are children waiting so long for new meds? expresspharma
June 10, 2020
COVID-19 and drug resistance are threatening to derail the progress made against the HIV, malaria and TB epidemics, and this may have a negative impact on child healthcare: Access to Medicine Foundation.